ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.902,35
0,31%
S&P 500
5.159,43
0,62%
US Dollar vs BRL
5,0691
-0,07%
Bitcoin
63.405,07
-0,93%
Brent Oil
82,805
-0,38%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Regulus Therapeutics Inc (RGLS)

  7. Regulus Therapeutics Inc (RGLS) Notícias

RGLS

Regulus Therapeutics (RGLS)

Regulus Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RGLS
DataHoraFonteTítuloCódigoCompanhia
06/05/202409:00PR Newswire (US)Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
30/04/202409:00PR Newswire (US)Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast SeriesNASDAQ:RGLSRegulus Therapeutics Inc
21/03/202417:05PR Newswire (US)Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
12/03/202407:32PR Newswire (US)Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of EquityNASDAQ:RGLSRegulus Therapeutics Inc
12/03/202407:30PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
18/01/202422:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
12/01/202418:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGLSRegulus Therapeutics Inc
10/01/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RGLSRegulus Therapeutics Inc
02/01/202418:05PR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
27/12/202318:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RGLSRegulus Therapeutics Inc
22/11/202310:00PR Newswire (US)Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
09/11/202318:39Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGLSRegulus Therapeutics Inc
09/11/202318:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
09/11/202318:05PR Newswire (US)Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
02/11/202309:00PR Newswire (US)Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
19/10/202309:00PR Newswire (US)Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
20/09/202308:00PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
13/09/202309:00PR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
05/09/202309:00PR Newswire (US)Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
23/08/202309:00PR Newswire (US)Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023NASDAQ:RGLSRegulus Therapeutics Inc
08/08/202317:05PR Newswire (US)Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
02/08/202309:00PR Newswire (US)Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
18/07/202309:00PR Newswire (US)Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
27/06/202309:00PR Newswire (US)Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
23/06/202317:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RGLSRegulus Therapeutics Inc
23/06/202309:00PR Newswire (US)Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of DirectorsNASDAQ:RGLSRegulus Therapeutics Inc
20/06/202309:00PR Newswire (US)Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's HospitalNASDAQ:RGLSRegulus Therapeutics Inc
13/06/202317:56Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RGLSRegulus Therapeutics Inc
12/06/202317:46Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:RGLSRegulus Therapeutics Inc
12/06/202309:00PR Newswire (US)Regulus Therapeutics Strengthens Research & Development LeadershipNASDAQ:RGLSRegulus Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RGLS

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AZEV4
AZEVEDO PN
BOV
LUPA3
LUPATECH ON
BOV
BRKM5
BRASKEM PNA
BOV
BHIA3
Grupo Casas Bahia ON
BOV
TELB4
TELEBRAS PN
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
PRIO3
PETRORIO ON
BOV
TPIS3
TRIUNFO PART ON
BOV
AZEV3
AZEVEDO ON
BOV
KRSA3
Kora Saude Participacoes... ON
BOV
MNPR3
MINUPAR ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
ETER3
ETERNIT ON
BOV
HAGA3
HAGA ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados